US-based pharmaceutical company Moderna has dosed the first subject in the US in its Phase III Nova 301 clinical trial of its investigational norovirus vaccine, mRNA-1403.
The Nova 301 trial aims to evaluate the vaccine’s efficacy, safety and immunogenicity on a global scale.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,